Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
Bibliographic Data
| ID | 15808291 |
|---|---|
| Authors | Kerstin Noëlle Vokinger (0000-0002-6997-7384, Dana-Farber Cancer Institute, corresponding author), Aaron S Kesselheim (0000-0002-8867-2666, Brigham and Women's Hospital), C Glaus (University of Zurich), Camille E G Glaus (University of Zurich), Thomas J Hwang (0000-0003-0717-1497, Brigham and Women's Hospital, corresponding author) |
| Year | 2022 |
| Volume | 3 |
| Issue | 8 |
| Pages | e222685-e222685 |
| Publication date | 2022-08-19 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | JAMA Health Forum (JOURNAL) |
| Journal identifiers | ISSN: 2689-0186 • E-ISSN: 2689-0186 |
| Publisher | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/jamahealthforum.2022.2685 |
| OpenAlex | W4292367025 |
| Language | EN |
| Citations received | 2 |
| References cited | 13 |
Importance The number of drugs approved through the accelerated approval or conditional marketing authorization pathways has increased with unclear evidence of their therapeutic value. Objectives To assess the therapeutic value of drug indications granted accelerated approval in the US or conditional marketing authorization in the European Union (EU) overall and for cancer indications. Design, Setting, and Participants This cohort study used the public databases of the US Food and Drug Administration and the European Medicines Agency to identify all drugs (initial and supplemental indications) granted accelerated approval in the US or conditional marketing authorization (initial indications only) in the EU between January 1, 2007, and December 31, 2021. Therapeutic value ratings were obtained from national health authorities in Germany, France, and Canada. Main Outcomes and Measures Descriptive statistics were used to assess the proportion of accelerated approvals and conditional marketing authorizations overall and for cancer vs noncancer indications rated as having high added therapeutic value. Results The cohort included 146 drug indications (94 first indications, 52 supplemental indications) in the US and 58 (all first indications) in the EU. Most drugs were approved for cancer (122 [83.6%] in the US; 40 [69.0%] in the EU). Therapeutic value ratings were available for 90 drug indications (61.6%) in the US and 56 (96.6%) in the EU. Overall, 35 drug indications granted accelerated approval (38.9%) and 21 granted conditional marketing authorization (37.5%) had high added therapeutic value in the US and EU, respectively, at the time of approval. The proportions of indications rated as having high added therapeutic value were 36.0% (27 of 75) for cancer vs 53.3% (8 of 15) for noncancer indications in the US and 30.8% (12 of 39) for cancer vs 52.9% (9 of 17) for noncancer indications in the EU. Conclusions and Relevance In this cohort study, among new drug indications approved through the accelerated approval or conditional marketing authorization pathways in the US and Europe from 2007 to 2021, 38.9% and 37.5%, respectively, demonstrated high therapeutic value. A substantially lower proportion of cancer indications than noncancer indications were rated as having high therapeutic value. Policy makers and regulators should increase enforcement of timely postapproval study completion for drugs qualifying for these pathways
Agency (philosophy · Authorization · Bioinformatics · Business · Cohort · Drug · European union · Family medicine · Marketing authorization · Value (mathematics · Health Systems, Economic Evaluations, Quality of Life · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare · Internal Medicine · Pharmacology
| Unique citing works | 2 |
|---|---|
| Citations per year | 1 |
| Citation span | 2024 - 2025 (2) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 2 |